Solid Dosage
GEA supplies highly specialized solutions for manufacturing inhalable drugs ranging from dry powder blending, spray drying to particle engineering capabilities.
Inhalables and aerosols, no matter whether they are in liquid or solid form, must be delivered to the oral cavity or the greater respiratory system.
Inhalation is often the preferred drug delivery method for lung diseases, offering a number of advantages for both patients and medical professionals for the administration of vaccines and other biological drugs. Producing powders for inhalation is relatively straightforward on a small scale; but, it can be hard to replicate at a commercial level.
To facilitate the process, GEA has developed a highly specialized spray drying system that offers large-scale particle engineering capabilities. This makes it possible to accurately manipulate the aerodynamic size and flow properties of particles to produce fine, free-flowing powders for applications such as commercializing biological compounds including hormones, peptides and proteins that risk degradation if ingested.
When it comes to mixing and blending very fine powders, homogeneity and stability are key factors during the production of inhalable drugs. As such, GEA also offers production-scale mixing and blending solutions to produce inhalable products (dry powders and suspensions).
The TRV high-speed blender, a standalone PharmaConnect® module, is particularly suitable for the rapid batch blending of small quantities of APIs with base excipients. By combining the high surface area of the main impeller blade with the directional effects of the feeder blade, rapid, homogenous and stable blends can be produced in a reproducible manner.
Affichage de 4 sur 15
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Continuous Processing is becoming more and more important in the pharmaceutical industry. GEA takes the lead in introducing this innovative technology with ConsiGma® - continuous high-shear granulation and drying lines.
At GEA we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product life-cycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
Pour nous, chez GEA, la réduction des déchets est importante. Nous sommes conscients qu’en exploitant la puissance de la technologie de la lyophilisation, nous pouvons transformer les denrées alimentaires en excédent en produits de valeur qui dureront longtemps, pour aider à réduire les déchets, allonger la durée de conservation et mettre en place un système agroalimentaire plus résilient pour les générations à venir.
Lorsque le producteur de denrées alimentaires à base végétale sud-coréen Pulmuone a mis GEA au défi de moderniser ses nouilles froides traditionnelles, les « naengmyeon », les spécialistes R&D de GEA ont saisi la balle au bond. Ils ont aidé l’entreprise à développer un plat, qui est aujourd’hui une vraie réussite commerciale et dont la production consomme moins d’eau et d’électricité que les méthodes qui existaient auparavant. Le résultat est, par ailleurs, fidèle aux origines traditionnelles de ce plat et aux racines de Pulmuone, qui sont la santé, le bien-être et le développement durable.